Literature DB >> 35393527

A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.

Huimin Liu1, Wei Liu1, Ru Li1, Yang Jiao1, Wenyang Huang1, Shuhua Yi1, Rui Lv1, Shuhui Deng1, Gang An1, Tingyu Wang1, Weiwei Sui1, Mingwei Fu1, Yaozhong Zhao1, Lugui Qiu1, Dehui Zou2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35393527     DOI： 10.1038/s41409-022-01655-0

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.174


× No keyword cloud information.
  4 in total

1.  Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.

Authors:  Benigno C Valdez; Yago Nieto; David Murray; Yang Li; Guiyun Wang; Richard E Champlin; Borje S Andersson
Journal:  Exp Hematol       Date:  2012-06-09       Impact factor: 3.084

2.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

3.  Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity.

Authors:  Youwu Shi; Peng Liu; Shengyu Zhou; Jianliang Yang; Xiaohong Han; Xiaohui He; Changgong Zhang; Lin Gui; Yan Qin; Sheng Yang; Liya Zhao; Jiarui Yao; Bo Jia; Shuxiang Zhang; Yan Sun; Yuankai Shi
Journal:  Asia Pac J Clin Oncol       Date:  2017-01-19       Impact factor: 2.601

4.  Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.

Authors:  T Kuittinen; E Jantunen; E Vanninen; H Mussalo; O Vuolteenaho; M Ala-Kopsala; T Nousiainen; J Hartikainen
Journal:  Eur J Haematol       Date:  2006-08       Impact factor: 2.997
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.